Specialized iNANO lecture: Nanobody disease targeting as a new paradigm for imaging and therapy
Tony Lahoutte, Department of Nuclear Medicine, University Hospital Brussels (UZBrussel), Belgium
Info about event
Time
Location
iNANO AUD (1593-012), Gustav Wieds Vej 14, 8000 Arhus C
Tony Lahoutte1,2
1 Department of Nuclear Medicine, University Hospital Brussels (UZBrussel), Belgium & 2 Lab of In vivo Cellular and Molecular Imaging (ICMI), Free University Brussels,Belgium
Nanobody disease targeting as a new paradigm for imaging and therapy
Nanobodies are small (10-15kD) antigen-binding proteins derived from the variable heavy-chain domain (VHH) of unique single-chain antibodies that are naturally present in camelidae. Due to their beneficial biochemical and pharmacokinetic properties, nanobodies are ideally suited as tracers for noninvasive molecular imaging. Nanobodies are highly soluble and stable. They invade dense cellular structures and are quickly removed from the circulation via renal clearance. Hence, nanobody-derived tracers can generate high contrast images fast after injection and, when labeled with high-energetic radionuclides, can deliver a lethal radiotoxic dose at a specific site. Here we will present an overview of our preclinical and clinical experience with nanobodies for nuclear and optical imaging and targeted radionuclide therapy, focusing mostly on oncological applications.
Host: Professor Kurt V. Gothelf, iNANO & Dept. of Chemistry, Aarhus University